This site is intended for Healthcare professionals only.
×

Zydus Cadila gets USFDA nod to market alcohol abstinence drug


Zydus Cadila gets USFDA nod to market alcohol abstinence drug

New Delhi: Drug firm Zydus Cadila has received approval from the US health regulator to market Acamprosate calcium delayed-release tablets used for maintenance of abstinence from alcohol in the US market.

“Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Acamprosate calcium delayed-release tablets, 333 mg”, Cadila Healthcare said in a BSE filing.

The drug will be produced at the groups formulations manufacturing facility at Baddi, it added.

“This medication is used for maintenance of abstinence from alcohol in patients with alcohol dependence”, Cadila Healthcare said.

The group now has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process in financial year 2003 -04, it added.

The following two tabs change content below.
Ruby Khatun

Ruby Khatun

Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: PTI
0 comment(s) on Zydus Cadila gets USFDA nod to market alcohol abstinence drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted